Top Page
Inspira Technologies Oxy BHN
(NASDAQ:IINN)
Inspira Technologies Oxy BHN (IINN) vs. SPDR S&P 500 ETF (SPY)
Inspira Technologies Oxy BHN Business Overview & Revenue Model
Inspira Technologies Oxy BHN Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 289.00K | 0.00 | 0.00 | -4.68M | 0.00 | 0.00 |
| Gross Profit | 2.00K | -488.00K | -406.00K | -5.04M | -218.00K | -203.00K |
| EBITDA | -7.16M | -11.10K | -10.87M | -14.68M | -16.72M | -6.96M |
| Net Income | -6.40M | -11.05K | -11.29M | -4.00M | -16.96M | -7.23M |
Balance Sheet | ||||||
| Total Assets | 4.45M | 8.07M | 9.31M | 16.01M | 25.87M | 987.00K |
| Cash, Cash Equivalents and Short-Term Investments | 2.13M | 5.78M | 7.36M | 13.90M | 23.75M | 496.00K |
| Total Debt | 640.00K | 2.51M | 878.00K | 1.46M | 1.48M | 2.32M |
| Total Liabilities | 3.17M | 3.75M | 3.57M | 3.19M | 5.52M | 2.69M |
| Stockholders Equity | 1.28M | 4.32M | 5.74M | 13.63M | 20.35M | -1.70M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -9.54M | -9.96M | -7.68M | -8.05M | -1.90M |
| Operating Cash Flow | 0.00 | -9.37M | -9.76M | -7.38M | -7.88M | -1.88M |
| Investing Cash Flow | 0.00 | 1.49M | 4.59M | -7.25M | -246.00K | -26.00K |
| Financing Cash Flow | 0.00 | 7.90M | 3.45M | -399.00K | 30.42M | 2.29M |
Inspira Technologies Oxy BHN Technical Analysis
Inspira Technologies Oxy BHN Risk Analysis
Inspira Technologies Oxy BHN Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $3.59B | -16.38 | -17.63% | ― | 8.97% | -1024.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $67.65M | -1.16 | -73.73% | ― | 15.59% | 4.13% | |
47 Neutral | $174.07M | -3.09 | -34.75% | ― | 15.19% | -3.32% | |
46 Neutral | $9.53M | -0.16 | -179.63% | ― | 147.74% | 73.23% | |
44 Neutral | $39.57M | -3.32 | -96.15% | ― | -8.97% | 47.29% | |
42 Neutral | $26.79M | -1.63 | ― | ― | ― | ― |
Inspira Technologies Oxy BHN Corporate Events
On January 29, 2026, Inspira Technologies announced that its FDA-cleared INSPIRA ART100 system has completed full clinical evaluation and progressed into a budgeted procurement execution process at a leading U.S. academic medical center ranked among the top hospitals nationwide. The ART100, which has successfully treated roughly 30 patients across life-saving procedures, surgeries and transplants at this institution, has moved from pilot use into the hospital’s standard clinical workflow with the clinical decision-making phase concluded, marking the first time the system has advanced from evaluation to a formal budgeted procurement pathway at a major U.S. academic center, a milestone the company views as validating the system’s real-world clinical performance and strengthening its U.S. commercial positioning.
The most recent analyst rating on (IINN) stock is a Sell with a $0.74 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On January 21, 2026, Inspira Technologies announced that two previously disclosed binding purchase orders worth $22.5 million and $27 million, first reported on July 2 and August 19, 2025, have progressed to the final budgetary validation and fund allocation stage within relevant governmental procurement processes. Approximately 91% of the combined orders has passed commercial and administrative review and is now awaiting final budgetary authorization, the last administrative hurdle before fund release and operational execution, with payment and revenue from these contracts expected over the 2026 fiscal cycle as governmental budget approvals and deployment milestones are completed; the company says it has finished internal preparations and remains focused on converting this contracted backlog into delivered systems and recognized revenue, underscoring the potential for a meaningful boost to its 2026 operating performance and its positioning in international life-support procurement markets.
The most recent analyst rating on (IINN) stock is a Sell with a $0.84 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On January 8, 2026, Inspira Technologies outlined a strategic vision and proposed transaction framework for expanding into breast cancer liquid biopsy diagnostics through the acquisition of an advanced platform focused on circulating tumor cells, alongside a concurrent $15 million equity investment at a pre-money valuation of $180 million. The deal is structured so that up to 40% of Inspira’s fully diluted share capital would be issued to acquire the liquid biopsy business, while existing shareholders of record before closing would receive contingent value rights (CVRs) designed to ensure they capture future economic benefits from the company’s core respiratory and life-support technologies, including potential dividends and proceeds from any future strategic transactions involving those assets; the company emphasized that its current FDA-cleared ART100 deployments and commercial pipeline remain on track, with up to $12 million of the new capital earmarked to fund and accelerate its ongoing respiratory and blood-monitoring operations, and the parties are targeting definitive agreements within about four weeks of a January 5, 2026 term sheet.
The most recent analyst rating on (IINN) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On January 5, 2026, Inspira Technologies Oxy B.H.N. Ltd. signed a non-binding term sheet to acquire an advanced liquid biopsy cancer diagnostics business in an all-share deal, exchanging 40% of its fully diluted share capital and securing a concurrent $15 million strategic equity investment at a pre-money valuation of $180 million. The move would shift Inspira into the fast-growing liquid biopsy market via a development-ready platform that uses AI to analyze circulating tumor cells, initially focused on breast cancer, with plans to pursue FDA 510(k) clearance and benefit from an existing reimbursement code. To bridge the period until a definitive acquisition agreement, Inspira also issued a binding senior convertible debenture on January 5, 2026, lending the target company $1 million at 10% annual interest, with conversion features tied to Tel Aviv Stock Exchange rules and a 19.99% ownership cap. The company intends to allocate up to $12 million of the new equity proceeds to support its existing respiratory and blood monitoring operations, while a contingent value rights structure is designed to preserve the economic upside from these legacy assets exclusively for current shareholders, underscoring management’s effort to mitigate dilution and reposition Inspira as a dual-platform MedTech player spanning life-support and oncology diagnostics.
The most recent analyst rating on (IINN) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Inspira Technologies Oxy B.H.N. Ltd., an Israeli foreign private issuer listed in the United States, operates within the medical technology and healthcare sector, though this filing focuses on its corporate governance and regulatory compliance rather than its products or services.
On December 30, 2025, the company convened its Annual and Extraordinary General Meeting of Shareholders, which was initially adjourned at 4:00 p.m. Israel time due to lack of quorum but successfully reconvened and held at 6:00 p.m., when a quorum was present and shareholders approved the agenda item described in the previously distributed notice and proxy statement; the resulting Form 6-K has been incorporated by reference into several of Inspira Technologies’ existing U.S. securities registration statements, underscoring its ongoing compliance with SEC reporting and governance requirements.
The most recent analyst rating on (IINN) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On December 23, 2025, Inspira Technologies Oxy B.H.N. Ltd. reaffirmed that previously announced binding purchase orders totaling $49.5 million remain valid and in full force, based on confirmations from its distribution partner. The company said the payment and execution framework for these orders has been rescheduled to begin with the 2026 fiscal year, aligning cash collection and revenue recognition with regulatory sequencing, technical implementation needs, and institutional funding timelines for large-scale international healthcare deployments. By coordinating closely with regulators, distribution partners, and funding organizations, Inspira aims to reduce execution risk, improve operational visibility, and support a phased rollout of its technologies across target markets, with further updates expected as 2026 regulatory and deployment milestones are reached.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On December 12, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced a registered direct offering agreement with YA II PN, Ltd., involving the issuance of 1,565,217 ordinary shares at $1.15 per share, expected to generate $1.8 million in gross proceeds. Additionally, the company entered into a Standby Equity Purchase Agreement (SEPA) with YA, allowing for up to $25 million in equity financing over 36 months. These financial maneuvers aim to bolster Inspira’s working capital and support its strategic roadmap, enhancing its operational flexibility and market positioning.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On December 9, 2025, Inspira Technologies announced that it has been granted a patent in Japan for its Convertible Dual Lumen Cannula device, securing exclusive rights in a major medical device market until 2041. This patent complements their existing U.S. patent, enhancing their position in two of the largest healthcare economies. The innovative design of the cannula allows conversion from single to dual-lumen intravascularly, potentially reducing infection risks and procedural costs. This development solidifies Inspira’s foundation for respiratory support platforms and future disposable revenue streams.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On December 3, 2025, Inspira Technologies announced a strategic expansion of its blood laboratory capabilities, marking a significant step in its evolution towards cutting-edge diagnostic technologies. This expansion involves moving to a larger facility, increasing recruitment of specialized personnel, and upgrading research instrumentation. The new laboratory is expected to enhance sample processing capacity and integrate advanced diagnostic technologies, positioning Inspira for accelerated growth and addressing high-value medical needs. This development is seen as a foundation for aggressive business growth, potentially generating long-term value for patients and shareholders.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Inspira Technologies Oxy B.H.N. Ltd. has announced its upcoming Annual and Extraordinary General Meeting of Shareholders, scheduled for December 30, 2025, in Ra’anana, Israel. The meeting will address several key proposals, including the re-appointment of Ziv Haft as the company’s independent auditor, the re-election of board members, and the approval of restricted share units for a new director. This meeting is significant for stakeholders as it involves decisions on leadership and financial oversight, impacting the company’s strategic direction and governance.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On November 13, 2025, Inspira Technologies announced the completion of a clinical study for its HYLA blood sensor, a non-invasive device designed for real-time blood monitoring. The study showed accuracy levels between 95% to 99%, and the company is now moving towards final validation and regulatory submission. This development enhances Inspira’s market positioning by potentially offering a disruptive solution in critical-care environments, supporting patient safety and workflow efficiency.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On November 6, 2025, Inspira Technologies announced the completion of its regulatory submission for the ART100 system to the UAE Ministry of Health and Prevention, with final approval expected soon. This milestone is part of Inspira’s strategy to expand in the Gulf region, leveraging the UAE’s efficient regulatory framework. The anticipated authorization is expected to enhance regional partnerships and unlock commercialization potential across the Middle East’s healthcare networks.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.